[HTML][HTML] Immune cell profiling during switching from natalizumab to fingolimod reveals differential effects on systemic immune-regulatory networks and on trafficking of …
L Lohmann, C Janoschka… - Frontiers in …, 2018 - frontiersin.org
Leukocyte sequestration is an established therapeutic concept in multiple sclerosis (MS) as
represented by the trafficking drugs natalizumab (NAT) and fingolimod (FTY). However, the …
represented by the trafficking drugs natalizumab (NAT) and fingolimod (FTY). However, the …
Immune Cell Profiling During Switching from Natalizumab to Fingolimod Reveals Differential Effects on Systemic Immune-Regulatory Networks and on Trafficking of …
L Lohmann, C Janoschka… - Frontiers in …, 2018 - europepmc.org
Leukocyte sequestration is an established therapeutic concept in multiple sclerosis (MS) as
represented by the trafficking drugs natalizumab (NAT) and fingolimod (FTY). However, the …
represented by the trafficking drugs natalizumab (NAT) and fingolimod (FTY). However, the …
Immune Cell Profiling During Switching from Natalizumab to Fingolimod Reveals Differential Effects on Systemic Immune-Regulatory Networks and on Trafficking of …
L Lohmann, C Janoschka… - Frontiers in …, 2018 - pubmed.ncbi.nlm.nih.gov
Leukocyte sequestration is an established therapeutic concept in multiple sclerosis (MS) as
represented by the trafficking drugs natalizumab (NAT) and fingolimod (FTY). However, the …
represented by the trafficking drugs natalizumab (NAT) and fingolimod (FTY). However, the …
[HTML][HTML] Immune Cell Profiling During Switching from Natalizumab to Fingolimod Reveals Differential Effects on Systemic Immune-Regulatory Networks and on …
L Lohmann, C Janoschka… - Frontiers in …, 2018 - ncbi.nlm.nih.gov
Leukocyte sequestration is an established therapeutic concept in multiple sclerosis (MS) as
represented by the trafficking drugs natalizumab (NAT) and fingolimod (FTY). However, the …
represented by the trafficking drugs natalizumab (NAT) and fingolimod (FTY). However, the …
[PDF][PDF] Lisa Lohmann, Claudia Janoschka, Andreas Schulte-Mecklenbeck, Svenja Klinsing1
L Kirstein, U Hanning, T Wirth… - Frontiers in …, 2018 - scienceopen.com
Leukocyte sequestration is an established therapeutic concept in multiple sclerosis (MS) as
represented by the trafficking drugs natalizumab (NAT) and fingolimod (FTY). However, the …
represented by the trafficking drugs natalizumab (NAT) and fingolimod (FTY). However, the …
Immune Cell Profiling During Switching from Natalizumab to Fingolimod Reveals Differential Effects on Systemic Immune-Regulatory Networks and on Trafficking of …
L Lohmann, C Janoschka… - Frontiers in …, 2018 - hero.epa.gov
Leukocyte sequestration is an established therapeutic concept in multiple sclerosis (MS) as
represented by the trafficking drugs natalizumab (NAT) and fingolimod (FTY). However, the …
represented by the trafficking drugs natalizumab (NAT) and fingolimod (FTY). However, the …
[PDF][PDF] Lisa Lohmann, Claudia Janoschka, Andreas Schulte-Mecklenbeck, Svenja Klinsing1
L Kirstein, U Hanning, T Wirth… - Frontiers in …, 2018 - researchgate.net
Leukocyte sequestration is an established therapeutic concept in multiple sclerosis (MS) as
represented by the trafficking drugs natalizumab (NAT) and fingolimod (FTY). However, the …
represented by the trafficking drugs natalizumab (NAT) and fingolimod (FTY). However, the …
Immune Cell Profiling During Switching from Natalizumab to Fingolimod Reveals Differential Effects on Systemic Immune-Regulatory Networks and on Trafficking of …
L Lohmann, C Janoschka… - Frontiers in …, 2018 - europepmc.org
Leukocyte sequestration is an established therapeutic concept in multiple sclerosis (MS) as
represented by the trafficking drugs natalizumab (NAT) and fingolimod (FTY). However, the …
represented by the trafficking drugs natalizumab (NAT) and fingolimod (FTY). However, the …